Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

providers and patients to better manage PKU. These programs include a state-of-the-art handheld device to measure blood Phe levels in PKU patients. Human studies are planned for 2010. Regulatory approval and commercial availability of the handheld blood Phe monitor is expected in the first half of 2011.
  • BMN-185 - IgA protease for IgA nephropathy: BioMarin is completing early preclinical work and expects to move to the next phase of research in the first half of 2010. IgA proteases have been shown to cleave IgA complexes, the deposition of which causes IgA nephropathy, an orphan kidney disorder with few treatment alternatives.
  • Additional early development candidates: BioMarin is working on multiple early development opportunities and expects to announce the next IND candidate in the first half of 2010.
  • BMN-103 - a-glucosidase (GAA) for Pompe Disease: BMN-103 is a highly phosphorylated GAA enzyme, which the company believes could result in more efficient uptake in cells and potentially lead to improved glycogen reduction in key affected muscle groups not addressed with current therapy. BioMarin continues to explore partnering options for this program.
  • 6R-BH4 Cardiovascular: BioMarin has decided to put the PAH opportunity for 6R-BH4 on hold, pending discussions with potential partners. Although the early data suggest a potential for 6R-BH4 to be a safe and efficacious therapy for PAH, BioMarin decided that the additional investment in time and resources required to demonstrate this effect is better allocated to other early pipeline candidates.
  • Non-GAAP Financial Information and Reconciliation

    The above results for the quarter and nine months ended September 30, 2009 and 2008, full year results for 2008 and financial guidance for 2009 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release, non-GAAP income is cal
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. BioMarin to Present at the Oppenheimer Healthcare Conference
    2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    7. BioMarin Announces FDA Approval for Kuvan
    8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    9. Rigel Announces Presentations at Two Investor Conferences
    10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
    11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/16/2009)... SOLON, Ohio, Dec. 16 HDT Engineered ... next generation technologies and a principal subcontractor for ... (MPL), led development of new anthropromorphic arm technology ... a prosthetic arm and hand, including a sense ... Defense Advanced Research Projects Agency (DARPA) Revolutionizing Prosthetics ...
    (Date:12/16/2009)... 16 A new application ... the clinical review of specialty pharmaceuticals has increased ... drugs reviewed while reducing costs. ,, AIM, a ... with health plan clients representing over 35 million ... (NYSE: WLP ), adapted the successful ...
    (Date:12/16/2009)... Dec. 16 EuroPharma, Inc. signs ... the use of super absorbency BCM-95® curcumin ... formulations. The exclusive distribution territory for ... food store channel and professional channel, which ... clinics. BCM-95® is a highly absorbable ...
    Breaking Medicine Technology:HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3Researcher says microchannels could advance tissue engineering methods 9601 1Researcher says microchannels could advance tissue engineering methods 9601 2Researcher says microchannels could advance tissue engineering methods 9601 3Researcher says microchannels could advance tissue engineering methods 9601 4Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024 54657 1Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024 54657 2Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024 54657 3Wyeth Announces Full Redemption of Floating Rate Convertible Senior Debentures Due 2024 54657 4Chicago Mayor Honors Astellas Excellence in Learning Development 54654 1Chicago Mayor Honors Astellas Excellence in Learning Development 54654 2
    ... - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces that ... trial of ZIO-201 (isophosphoramide mustard,- IPM) to ... the,European Society of Medical Oncology (ESMO) meeting ... abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) In ...
    ... Late-breaking Phase III,clinical trial data presented today ... Haemostasis (ISTH) Congress demonstrate,that once-daily rivaroxaban achieved ... (VTE) in patients undergoing,knee replacement surgery in ... of care. Patients in the RECORD3,(REgulation of ...
    Other Medicine Technology:Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5
    (Date:12/16/2009)... 16, 2009 -- Every year in the United States, ... patients die of the disease, making it the second ... lung cancer. , As researchers and clinicians fervently look ... generating thousands of studies producing more and more promising ... cancer and genetics at Case Western Reserve University School ...
    (Date:12/16/2009)... WASHINGTON, Dec. 16 Losing has never felt ... knows maintaining his healthy new lifestyle means continuing to ... Drinking fat free milk is one healthy choice that ... a simple step everyone can take. Every glass of ... muscle, potassium to help maintain normal blood pressure, and ...
    (Date:12/16/2009)... most widely used human embryonic stem cell lines lack ... that must be addressed to ensure that all sectors ... a University of Michigan research team. ,, In the ... analyzed 47 embryonic stem cell lines, including most of ... scientists determined the genetic ancestry of each line and ...
    (Date:12/16/2009)... long-term goal, researchers say , , WEDNESDAY, Dec. 16 ... predict whether a patient will suffer a second stroke ... is an important new tool because studies have shown ... a first stroke are more likely to die or ... Hospital and Harvard Medical School, said in an American ...
    (Date:12/16/2009)... Wellcome Trust Sanger Institute announce the first comprehensive analyses ... by mutations in the DNA of cancer cells which ... a malignant melanoma and a lung cancer, reveal for ... genomes of two cancers. , Lung cancer causes around ... associated with smoking. The number of mutations found suggest ...
    Breaking Medicine News(10 mins):Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6
    ... with a second newer agent has proven to be effective ... be published in its July 7th special HIV/AIDS issue. ... 18 nations and more than 30 centers in the United ... resistant HIV the potential of receiving two investigational new drugs ...
    ... police inquiries as focus shifted to Australia. ... attacks in UK raided two hospitals in Western Australia and ... Indian. ,However, WA Premier Alan Carpenter said he ... ,"There is nothing that has been presented to ...
    ... a blood-clotting protein found in circulating blood, has been ... neuronal cells , a process that is necessary for ... ,The findings by researchers at the University ... explain why the human body is unable to repair ...
    ... Didrick of Naples, Florida, has come up with a fascinating ... in 150 persons do lose a digit , it is ... because it has no batteries, electronics, servos or actuators. Instead, ... the surviving part of the wearer's finger, curls a set ...
    ... a way to produce blood vessels by engineering tissues ... ,Researchers at the University at Buffalo Department of Chemical ... an excellent source of adult stem cells, containing smooth ... cells can be used in regenerative medicine for cardiovascular ...
    ... conducted by Henley Management College and the University of Milan ... age of 65 is significantly higher than it is ... study was to make the first step in the modelling ... prescribing funds. ,The research found that the mean ...
    Other Medicine News:Health News:New Drugs Show Promise in Fighting Drug-Resistant HIV 2Health News:New Drugs Show Promise in Fighting Drug-Resistant HIV 3Health News:More Indian Doctors Questioned in Australia as UK Terror Plot Inquiry Widens 2Health News:Fibrinogen may Inhibit Spinal Cord Regeneration 2Health News:A Mechanical Prosthetic Close to the Real Thing 2Health News:New Blood Vessels can Be Created from Bone Marrow Stem Cells: Study 2
    Blunt tipped forceps with long thin tips (3 mm) angled at approximately 120. For grasping of subretinal membranes. Color Coding: Gold....
    Blunt tipped forceps with entire interior surface of tip serrated. For general purpose membrane grasping (coarse membranes)....
    Microforceps: Claes ILM Forceps...
    0,6 mm (23 gauge) blunt tipped forceps with entire interior surface of tip serrated. For general purpose membrane grasping (coarse membranes)....
    Medicine Products: